Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Similar articles for PubMed (Select 23576871)

2.

Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).

[No authors listed]

NIH Consens Statement. 1998 Nov 16-18;16(2):1-37. Review.

PMID:
10868163
3.

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.

Christman AK, Fermo JD, Markowitz JS.

Pharmacotherapy. 2004 Aug;24(8):1020-36. Review.

5.

Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Childress AC.

Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. Epub 2012 May 18. Review.

PMID:
22610723
6.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
7.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
8.

[Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review].

Mészáros A, Czobor P, Bálint S, Simon V, Bitter I.

Psychiatr Hung. 2007;22(4):259-70. Hungarian.

PMID:
18167421
10.
11.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
12.
14.

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Wigal SB.

CNS Drugs. 2009;23 Suppl 1:21-31. doi: 10.2165/00023210-200923000-00004. Review.

PMID:
19621975
16.

To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?

van de Loo-Neus GH, Rommelse N, Buitelaar JK.

Eur Neuropsychopharmacol. 2011 Aug;21(8):584-99. doi: 10.1016/j.euroneuro.2011.03.008. Epub 2011 May 6. Review.

PMID:
21530185
17.

Attention deficit hyperactivity disorder: anxiety phenomena in children treated with psychostimulant medication for 6 months or more.

Vance AL, Luk ES, Costin J, Tonge BJ, Pantelis C.

Aust N Z J Psychiatry. 1999 Jun;33(3):399-406.

PMID:
10442797
18.

Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.

Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12.

PMID:
22780921
19.
20.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk